Drug Discovery Outsourcing Market 2024-2028: Size and Limited manufacturing standardization; growth driven by the Product, Some of key Companies Positioned Strategically

The drug discovery outsourcing market size by Product (Small-molecules and Biologics), End-user (Big pharmaceutical companies, Small and medium-sized pharmaceutical companies, and Generic pharmaceutical companies), and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 1.79 billion. The market is expected to grow at a CAGR of   7.44% between 2024 and 2028.

• Pharmaceutical companies outsource drug discovery activities to maintain focus on their core competencies while leveraging the expertise and capabilities of external partners. However, inconsistent manufacturing standards pose significant risks to the quality, safety, efficacy, and reliability of the products and services delivered. These concerns stem from potential non-compliance with regulatory requirements and industry standards, which can hinder market growth. Pharmaceutical firms require their outsourcing partners to adhere to stringent manufacturing protocols to ensure the integrity and reliability of the drug discovery process. Inadequate infrastructure and subpar manufacturing standards can impede market expansion, as companies may hesitate to outsource if they doubt the compliance and integrity of the manufacturing processes.
• The North American drug discovery outsourcing market is experiencing robust growth, with the United States leading the charge due to its advanced healthcare infrastructure and high concentration of pharmaceutical companies, research institutions, and CDMOs. This dynamic ecosystem encourages collaboration and innovation in drug discovery technologies, resulting in increased adoption of outsourcing services. Significant investments in healthcare research and testing in the US, coupled with strong distribution networks and the increasing focus of pharmaceutical companies on drug discovery and development, further fuel market expansion. Keywords: drug discovery outsourcing, North America, United States, healthcare infrastructure, pharmaceutical companies, research institutions, CDMOs, collaboration, innovation, investments, healthcare research, testing, market growth, drug discovery, development.

Access the full report to know who are the other key countries segment-wise forecast and historic data

Some of the Key Companies:

• Aragen Life Sciences Pvt. Ltd.
• Aurigene Discovery Technologies
• Catalent Inc.
• Charles River Laboratories International Inc.
• Curia Global Inc.
• Domainex
• Eurofins Scientific SE
• Evotec SE
• GenScript Biotech Corp.
• LABORATORY CORPORATION OF AMERICA HOLDINGS
• Lonza Group Ltd.
• Lupin Ltd.
• Novotech Health Holdings
• Oncodesign Services
• PerkinElmer Inc
• QIAGEN NV
• Shanghai Medicilon Inc.
• Syngene International Ltd.
• Thermo Fisher Scientific Inc.
• WuXi AppTec Co. Ltd.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/